Cargando…
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial
IMPORTANCE: Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials. OBJECTIVE: To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients...
Autores principales: | Johnson, Helen M., Lin, Heather, Shen, Yu, Diego, Emilia J., Krishnamurthy, Savitri, Yang, Wei T., Smith, Benjamin D., Valero, Vicente, Lucci, Anthony, Sun, Susie X., Shaitelman, Simona F., Mitchell, Melissa P., Boughey, Judy C., White, Richard L., Rauch, Gaiane M., Kuerer, Henry M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502524/ https://www.ncbi.nlm.nih.gov/pubmed/37707811 http://dx.doi.org/10.1001/jamanetworkopen.2023.33933 |
Ejemplares similares
-
Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016) -
Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014) -
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer
por: Lim, Bora, et al.
Publicado: (2020) -
Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial
por: Shen, Yu, et al.
Publicado: (2023) -
Omission
Publicado: (1881)